RNA Stock Price | Avidity Biosciences Inc P/E, Revenue, EPS, & Forecasts

Avidity Biosciences Inc • RNA

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Avidity Biosciences Inc

Ticker

RNA

Trading on

NASDAQ

ISIN

US05370A1088

Industry

Biotechnology

Sector

Healthcare

CEO

Sarah Boyce

Headquarters

10578 Science Center Drive, San Diego, CA, United States, 92121

Employees

391

Website

aviditybiosciences.com

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's product candidate Delpacibart etedesiran is for the treatment of myotonic dystrophy type 1 and is currently in phase 3 trial. Its other products in pipeline include Delpacibart zotadirsen for the treatment of duchenne muscular dystrophy, which is under phase 2 clinical development trial; and Delpacibart braxlosiran for the treatment of facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare genetic cardiomyopathies for PRKAG2 syndrome and PLN cardiomyopathy. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Metrics

BasicAdvanced

Market cap

$4B

P/E ratio

EPS

-$2.89

Dividend Yield

0.00%

Beta

1.02

Forward P/E ratio

EBIDTA

$-376M

Ex dividend date

Price & volume

Market cap

$4B

Average daily volume

1.4M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

367.35

Price to book

2.71

Earnings

EPS

-$2.89

EPS estimate (current quarter)

-$0.78

EPS estimate (next quarter)

-$0.77

EBITDA

$-376M

Revenues (TTM)

$10.9M

Revenues per share (TTM)

$0.10

Technicals

Beta

1.02

52-week High

$56.00

52-week Low

$21.56

50-day moving average

$31.19

200-day moving average

$38.88

Short ratio

12.51

Short %

17.36%

Management effectiveness

ROE (TTM)

33.47%

ROA (TTM)

21.61%

Profit margin

0.00%

Gross profit margin

$-293M

Operating margin

4,069.63%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

35.60%

Share stats

Outstanding Shares

120M

Float

92.7M

Insiders %

5.03%

Institutions %

107.33%

Analyst Insights & forecasts

100% Buy

0% Hold

0% Sell

Based on information from 11 analysts.

Average price target

$66.69

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.79

-$0.78

1.28%

Q1 • 24Beat

-$0.65

-$0.79

17.72%

Q2 • 24Beat

-$0.65

-$0.71

8.45%

Q3 • 24Beat

-$0.80

-$0.78

2.45%

Q4 • 24Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$2.3M

$-80.4M

3,441.70%

Q3 • 24

$3M

$-102M

3,439.52%

Q4 • 24

27.27%

27.19%

0.06%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$1.64B

$137M

8.37%

Q3 • 24

$1.56B

$139M

8.88%

Q4 • 24

4.69%

1.12%

6.10%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-65.6M

$-482M

$342M

$-67.3M

Q3 • 24

$-99.9M

$-64.2M

$13.7M

$-104M

Q4 • 24

52.21%

86.70%

95.99%

54.17%

QoQ growth

QuarterlyAnnual

Sentiment analysis

-1.5

Neutral

+1.5

-0.25

Last 30 days

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Avidity Biosciences Inc share?

Avidity Biosciences Inc shares are currently traded for undefined per share.

How many shares does Avidity Biosciences Inc have?

Avidity Biosciences Inc currently has 120M shares.

Does Avidity Biosciences Inc pay dividends?

No, Avidity Biosciences Inc doesn't pay dividends.

What is Avidity Biosciences Inc 52 week high?

Avidity Biosciences Inc 52 week high is $56.00.

What is Avidity Biosciences Inc 52 week low?

Avidity Biosciences Inc 52 week low is $21.56.

What is the 200-day moving average of Avidity Biosciences Inc?

Avidity Biosciences Inc 200-day moving average is $38.88.

Who is Avidity Biosciences Inc CEO?

The CEO of Avidity Biosciences Inc is Sarah Boyce.

How many employees Avidity Biosciences Inc has?

Avidity Biosciences Inc has 391 employees.

What is the market cap of Avidity Biosciences Inc?

The market cap of Avidity Biosciences Inc is $4B.

What is the P/E of Avidity Biosciences Inc?

The current P/E of Avidity Biosciences Inc is null.

What is the EPS of Avidity Biosciences Inc?

The EPS of Avidity Biosciences Inc is -$2.89.

What is the PEG Ratio of Avidity Biosciences Inc?

The PEG Ratio of Avidity Biosciences Inc is 0.

What do analysts say about Avidity Biosciences Inc?

According to the analysts Avidity Biosciences Inc is considered a buy.